Searchable abstracts of presentations at key conferences in endocrinology

ea0024oc2.4 | Oral Communications 2 (Brief Communications) | BSPED2010

Morbidity and Mortality of Infants with Salt Wasting Congenital Adrenal Hyperplasia in an Unscreened Population

Hird B E , Patel L , Tobi S , Clayton P E

Due to the non-specificity of symptoms in male neonates affected by salt-wasting (SW) CAH, it is hypothesised that a proportion die prior to diagnosis in countries lacking a newborn screening (NBS) programme, such as the UK. The aim of this study was to analyse 17-hydroxyprogesterone (17-OHP) in stored NBS blood spot samples, to detect undiagnosed cases of CAH. Samples were retrieved from storage for neonates who were born between 1994 and 2006, who subsequently died before 7 ...

ea0024p41 | (1) | BSPED2010

It’s not just Coeliac disease: gastroenterology referrals from a paediatric diabetes clinic

Lipscomb N C , Campbell E B , Imrie C

There is a well-recognised association between Coeliac disease and type 1 diabetes (T1DM). Four of our 68 patients have both conditions (5.9%). We present three other patients with T1DM and GI disease – two inflammatory bowel disease (IBD=2.9%) and one primary sclerosing cholangitis (PSC) and IBD (=1.5%).Case 1: Sixteen years old male, with T1DM from 13-year-old, developed diarrhoea and abdominal pain with no weight loss or blood pr. Investigation s...

ea0026p76 | Endocrine tumours and neoplasia | ECE2011

Management of type III neuroendocrine tumors of the stomach

Gilis-Januszewska A G J , Baczynska E B , Sowa-Staszczak A S S , Trofimiuk M T , Pach D P , Tomaszewska R T , Hubalewska-Dydejczyk A H D

Background: Type 3 neuroendocrine tumors of the stomach (type 3 NETV) are very rare subtypes of NETV with poor prognosis, not fully understood biology and not well investigated diagnostic and therapeutic procedures. The aim of the study was to analyze tumor biology and the outcome of differentiated treatment in patients with type 3 neuroendocrine tumors of the stomach.Methods: A prospective 10 years follow up of five patients with type 3 NETV treated in ...

ea0026p30 | Adrenal cortex | ECE2011

Is plasma mitotane level >30 mg/l a serious adverse event in patients with adrenocortical carcinoma (ACC)?: a retrospective analysis of the French COMETE network

Mauclere-Denost S M D , Tabarin A T , Drui D D , Chaillous L C , Salenave S S , Leboulleux S L , Chabre O C , Do-Cao C D C , Dubourg H D , Cuvelier M L C , Young J Y , Baudin E B

Background: Mitotane antitumor efficacy is related to plasma levels. Objective responses have been associated with mitotane plasma levels >14 mg/l. However, high plasma levels >20 or >30 mg/l are at higher risk of toxicity, especially neurotoxicity. National-based survey is lacking to evaluate the frequency and severity of high mitotane plasma levels. Our aim was to retrospectively describe serious adverse events (SAE).Methods: Mitotane plasm...